University of Zurich
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 1833-04-29
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.uzh.ch
Clinical Trials
1.0k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (647 trials with phase data)• Click on a phase to view related trials
Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling
- Conditions
- Heart FailureHeart Failure (for Example, Fluid Overload)
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 500
- Registration Number
- NCT07158086
- Locations
- 🇨🇭
University Hospital of Zurich, Zurich, Switzerland
Assessing How the Body Responds to Increased Phosphate Intake, and How This Response Depends on Age and Sex.
- Conditions
- AgingKidney DiseaseMineral Metabolism
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 40
- Registration Number
- NCT07149337
Exploring Biological Markers of Driver Fatigue for Enhanced Road Safety
- Conditions
- DrowsinessSleepinessFatigue
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 500
- Registration Number
- NCT07089342
- Locations
- 🇧🇪
Vias institute, Brussels, Belgium
Personalized Stimulation Loop for Neurorehabilitation in Parkinson: a Proof-of-principle Study
- Conditions
- Parkinson Disease
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 40
- Registration Number
- NCT07082595
- Locations
- 🇨🇭
University of Zurich, Zurich, Switzerland
Magnetic Resonance Imaging-guided Online Adaptive Radiotherapy of Pelvic Lymph Node Metastases
- Conditions
- Pelvic and Para-aortic Lymph Node Metastases
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 20
- Registration Number
- NCT07083648
- Locations
- 🇨🇭
Zurich University Hospital, Department of Radiation Oncology, Zürich, Zurich, Switzerland
- Prev
- 1
- 2
- 3
- 4
- 5
- 203
- Next
News
Arcturus Therapeutics to Present Phase 2 Data for ARCT-810 mRNA Therapy in Rare Genetic Disorder
Arcturus Therapeutics will host a virtual presentation on June 30, 2025, featuring Phase 2 interim data for ARCT-810, an investigational mRNA therapeutic for ornithine transcarbamylase deficiency.
Swiss Researchers Pioneer Multiomics-Based Cancer Treatment Predictions in First-of-Kind Clinical Study
Swiss researchers conducted the world's first clinical study using nine molecular biological technologies in parallel to predict optimal cancer treatments within four weeks, analyzing tumors from 116 melanoma patients.
Phase 1/2 KEYMAKER-U02 Trial: Pembrolizumab Shows Manageable Safety Profile in Stage IIIB-D Melanoma
Neoadjuvant pembrolizumab, alone or combined with vibostolimab or gebasaxturev, demonstrated a manageable safety profile in stage IIIB-D melanoma patients, with 95% experiencing at least one adverse event.